Letters, Statements and Analysis

Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.

 

2018

 

2017

 

2016

 

2015

 

2014

 

June

6/7/2018

AMCP supports S. 974 , the CREATES ACT (Creating and Restoring Equal Access to Equivalent Samples).   

May

5/9/2018

AMCP submits letter for the record to House Energy and Commerce committee in support of Opioid Legislation - H.R. 3528, H.R. 4275 and H.R. 4841   

5/8/2018

AMCP submits letter to Illinois Senate Committee opposing House Bill 4146 which prohibits formulary changes during a plan year   

April

4/12/2018

AMCP submits letter to New Jersey Assembly committee opposing Assembly Bill 881- prohibiting utilization management strategies   

AMCP submits letter to New Hampshire House committee opposing provisions of Senate Bill 332 - requiring coverage of all medication synchronization   

AMCP submits letter to New York Senate committee opposing provisions of Assembly Bill 4306 - mandating conditions for medication synchronization   

4/10/2018

AMCP submits letter to Energy and Commerce Chairman Walden and Ranking Member Pallone in support of H.R. 3545 – Overdose Prevention and Patient Safety Act   

AMCP submits letter to Representative Schweikert in support of H.R. 4841 – Standardizing Electronic Prior Authorization for Safe Prescribing Act   

4/5/2018

AMCP Submits letter to New Hampshire House Committee recommending amendments to Senate Bill 350 - Biological products dispensed by pharmacists   

March

3/30/2018

AMCP Submits Comments to USP on Proposed Section 2.20 General Notices   

3/29/2018

AMCP joins 12 stakeholder organizations in support of Colorado H.B. 1279 the mandatory e-prescribing of controlled substances.   

AMCP responds to the Agency for Healthcare Quality and Research (AHRQ) Request for Information Regarding Patient-Reported Outcome Measures.   

AMCP submits letter to Illinois State Insurance: Life and Health Committee opposing H.B 4146-prohibiting modifying an enrollee’s drug coverage   

3/21/2018

AMCP joins 66 other partnership members and stakeholder organizations in a letter of continued support for H.R. 3545 – the Overdose Prevention and Patient Safety Act.   

AMCP submits letter to Maryland House Health and Government Operations Committee supporting H.B 1716 and Insurance Carriers’ Access to the PDMP   

3/5/2018

AMCP submits comments to CMS on 2019 Draft Call Letter   

February

2/28/2018

AMCP submits letter to West Virginia Speaker of Delegates on House Bill 4524 and Establishing Guidelines for the Substitution of Certain Biologic Pharmaceuticals by Pharmacists.   

AMCP submits letter to Vermont House Committee on Health Care regarding Senate Bill 92 on Substitution of Interchangeable Biologic Products.   

AMCP submits letter to New Hampshire Senate Health and Human Services Committee on Senate Bill 350 regarding Interchangeable Biologic Products Dispensed by Pharmacists.   

AMCP submits letter to Connecticut Senate General Law Committee on Senate Bill 197 regarding Interchangeable Biologic Products.    

2/27/2018

AMCP submits letter to Wyoming Joint Labor, Health and Social Services Committee on Senate File 75 and Authorizing Pharmacists to Dispense Interchangeable Biologic Products.   

AMCP Submits Letter to Alaska House Finance Committee regarding Senate Bill 32 and the regulation of Biologic Product Substitutions.   

2/26/2018

AMCP joins 11 organizations in letter to the OIG in support of establishing a safe harbor provision that would encourage the development of additional value-based contracts for the Medicare and Medicaid populations.   

2/12/2018

AMCP Submits Letter to Speaker of Wisconsin Assembly regarding Assembly Bill 679 and the Regulations on Pharmacists Substituting Biological Products   

2/6/2018

AMCP joins other stakeholders in support of the CREATES Act   

January

1/30/2018

AMCP Delivers Remarks at FDA Opioid Policy Steering Committee Meeting on How the FDA Can Help Address the Opioid Epidemic   

1/17/2018

AMCP Submits Letter to Energy & Commerce Subcommittee on Health in Support of HR 2026 – The Pharmaceutical Information Exchange (PIE) Act   

AMCP sends letter to Michigan House Health Policy Committee citing concerns with HB 4472 and regulations on pharmacists substituting interchangeable biological products   

1/16/2018

AMCP Submits Comments to CMS on Medicare Advantage and Medicare Part D Proposed Rule   

Content for class "break" Goes Here